U87 Transfection Reagent (Glioblastoma Cells)

Catalog #3277 U87 Transfection Reagent, Size: 0.5 mL $196

Catalog #3278 U87 Transfection Reagent, Size: 1.5 mL $409

Transfection Reagent for U87 MG Cells (Glioblastoma Cells)

  • Two component formulation enhances lipid mediated transfection efficiency
  • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
  • Kit includes Transfection Enhancer reagent and recommended transfection protocol
  • High transfection efficacy in the presence of serum
  • Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
  • Reproducible transfection results
  • Works well for standard reverse transfection and high-throughput applications
  • Download in vitro U87 transfection protocol: [PDF]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 81% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems U87 Transfection Protocol: [PDF]

Download MSDS: [PDF]

U-87 MG Cell Line:

U-87 MG is a human glioblastoma cell line derived from a stage three 44 year-old Caucasian female. It has epithelial morphology. Grade IV glioma, also called glioblastoma multiforme (GBM), is the most common primary malignant brain tumor with about 16,000 new diagnoses each year in the United States. GBMs have a one-year survival rate of only 29.6 percent making it one of the most deadly types of cancer. This is a hypodiploid human cell line with the modal chromosome number of 44 occurring in 48 percent of cells. The rate of higher ploidy was 5.9 percent. Twelve markers were common to all cells. There was only one copy of normal X. N1, N6 and N9 were not found. U-87 MG cells are used as an vitro model of human glioblastoma cells to investigate the cytotoxic effect of chemotherapeutic drugs towards cancer cells.

Data:

U87 Cell Transfection Kit

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the U87 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).

Altogen Biosystems:

Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, elecroporation kits, and in vivo delivery reagents (peg-liposome, nanoparticle, lipid, and polymer-based; and tissue targeted: liver, pancreas, kidney). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen's Transfection Resource.    

Altogen Research Services:

Altogen Labs is a GLP compliant laboratory that provides preclinical contract research services (CRO). Pharma and biotechnology services include: transient and stable transfection (development of stable cell lines), liposome encapsulation (proteins, DNA, mRNA, siRNA), A-to-Z RNAi services, in vivo and in vitro toxicology, xenograft animal models, assay development, cell banking and cryopreservation services.